Due to the low occurrence probability of ROS1 fusion in lung cancer patients, this molecular subtype was often neglected in the past in clinical practice, and patients with ROS1 fusion were often treated with standard regimens such as chemotherapy for first-line. The gene discussed is ROS1; the disease is lung carcinoma.